Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History APRE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics APRE

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Aprea Therapeutics Inc

APRE
Current price
1.74 USD +0.01 USD (+0.58%)
Last closed 1.70 USD
ISIN US03836J1025
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 9 624 584 USD
Yield for 12 month -54.45 %
1Y
3Y
5Y
10Y
15Y
APRE
21.11.2021 - 28.11.2021

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania. Address: 3805 Old Easton Road, Doylestown, PA, United States, 18902

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

13.67 USD

P/E Ratio

Dividend Yield

Financials APRE

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures APRE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+1 502 581 USD

Last Year

+583 231 USD

Current Quarter

Last Quarter

+205 817 USD

Current Year

+1 480 263 USD

Last Year

+576 179 USD

Current Quarter

Last Quarter

+200 389 USD
EBITDA -15 233 977 USD
Operating Margin TTM -2 514.78 %
Price to Earnings
Return On Assets TTM -35.70 %
PEG Ratio
Return On Equity TTM -59.80 %
Wall Street Target Price 13.67 USD
Revenue TTM 1 284 475 USD
Book Value 2.82 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -57.30 %
Dividend Yield
Gross Profit TTM -8 961 755 USD
Earnings per share -2.34 USD
Diluted Eps TTM -2.34 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation APRE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM 7.49
Enterprise Value EBITDA 0.35
Price Book MRQ 0.62

Technical Indicators APRE

For 52 Weeks

1.41 USD 5.01 USD
50 Day MA 1.73 USD
Shares Short Prior Month 73 646
200 Day MA 2.72 USD
Short Ratio 2.19
Shares Short 72 909
Short Percent 1.49 %